Difference Between Peptide Clinics and General Medical Clinics in Australia
When you have been spending any time researching peptide therapy in Australia you have likely come across two types of significantly different places that sell it. On the one hand, there are general medical clinics, which most Australians are familiar with, that is, the GP practise or a specialist office. Contrarily, there exist specialty peptide clinics, enterprises that have been established with the express purpose of prescribing and selling peptide remedies to issues such as recovery, anti-ageing, hormone optimisation and body composition.
On the surface, the two may appear to be doing the same. After a prescription by a doctor, a peptide is prescribed. A pharmacy compounds it. You take it home. However, the reality is not as simple as it seems and it is important to realise that there are differences, which is important in case you are attempting to negotiate safely and legally within Australia.
An Australian GP practise or specialist office is a general medical clinic. These facilities are constructed on general healthcare. You visit it because of a sore throat up to a surgery referral. The physicians are registered by the Australian Health Practitioner Regulation Agency (AHPRA) and the practise licenced under the supervision of the medical board of Australia.
In the case of peptides, they can be prescribed by a general medical clinic, although usually under a rather limited scope. A GP may recommend a peptide drug, such as insulin, a GLP-1 receptor agonist to manage diabetes or obesity or semaglutide to manage weight loss, which is included in the approved category. They are drugs made in the form of a peptide that have been subjected to the entire regulatory approval process, are registered in the Australian Register of Therapeutic Goods (ARTG) and in most cases they have Pharmaceutical Benefits Scheme (PBS) subsidies placed over them.
Prescription of unapproved peptides such as BPC-157, CJC-1295, ipamorelin or thymosin alpha-1 is what a general medical clinic would least do. The majority of GPs merely lack specialised training, the compounding pharmacy contacts or the monitoring regimes to deal with such treatments. This does not mean that they are not allowed to prescribe them under some conditions. The reason is that the infrastructure and expertise are not in their normal practise.
In Australia, the model of peptide clinics is completely different. Those are the practises that are developed based on peptide therapy, which is frequently accompanied by other associated services such as hormone optimisation, longevity medicine, NAD+ therapy, weight management and performance health.
A normal patient experience in a peptide clinic has the following appearance. An initial visit is the first step and is typically through telehealth where a physician will take your medical history, discuss your objectives and request baseline blood tests. On getting the results returned the doctor will construct a customised peptide protocol, prescribe the required compounds and have a TGA-approved compounding pharmacy supply and ship the products straight to you. Follow-up visits cheque on your progression, change doses and take regular blood work.
Most of these clinics are online-based with telehealth consultation services being available across Australia. This model has been experiencing a surge in recent years led by demand by individuals in regional settings who are unable to visit specialist clinics and by the wider trend of generalisation of telehealth in Australian healthcare.
These clinics still have the AHPRA registered medical practitioners. They are equally qualified as any GP or specialist in the field of medicine. Their point of difference is their focus. A large number have also undertaken further education through organisations such as the Australasian Academy of Anti-Ageing Medicine (AAAM) or similar organisations, namely: peptide protocols, hormone management and regenerative medicine.
This is where it counts since whether it is a general medical clinic or a peptide clinic, the regulatory framework in Australia remains the same.
By the Poisons Standard, most therapeutic peptides are classified by the Therapeutic Goods Administration (TGA) as Schedule 4 (prescription-only) medicines. Human growth hormone is located in Schedule 8 (controlled drug). It implies that prescription and dispensing of peptides should be conducted by an AHPRA-registered medical practitioner and dispensary respectively. It is the case regardless of whether the prescription is made by a bulk-billing GP in the suburbs of Sydney or a peptide clinic that runs the telehealth programme.
The majority of peptides that are prescribed in peptide clinics such as BPC-157, CJC-1295, ipamorelin and thymosin beta-4 are not on the ARTG. They are illicit therapeutic goods. They are still legally prescribed, but in special channels by the doctors. They are the Special Access Scheme (SAS) which allows a doctor to make a detailed justification to the TGA to have an individual patient put on an individual prescription and the extemporaneous compounding exemption which is used by a pharmacist to have a medicine compiled on an individual prescription.
The TGA does not control the practise of clinical practise. That is on AHPRA and the health complaints body of the state or territory in question. However the TGA does keep an eye on the prescribing behaviour, and AHPRA has been looking into the prescribing conduct of those practitioners who prescribe outside accepted indications of prescribing without sufficient clinical justification.
The legal and regulatory environment is an identical one in both kinds of clinics. The variations exist in the scope, specialisation, cost and the nature of peptides that are usually prescribed.
Availability of telehealth: A large portion of peptide clinics do telehealth, which is why they are available throughout Australia. Telehealth is now becoming common in general clinics; however, the specialty of peptides is not usually included in the standard range of telehealth.
Not every peptide clinic is equal and this is where the consumers must be cautious. These developments have seen a variety of players enter the peptide therapy market in Australia, with some being well-established medical practises with strict guidelines and others being less ethical in their operations, focusing on sales rather than safety of the patients.
A valid peptide clinic must be ready to disclose the AHPRA registration number of the prescribing doctor, the name of the TGA-licenced compounding pharmacy with which they collaborate (and the licence number of the pharmacy) should be provided, a clear description of the monitoring procedure and required blood tests, transparent pricing with no hidden charges and a frank discussion of risks, side effects and regulatory status of the prescribed peptides.
Some of the red flags are clinics that urge you to buy peptides on your own or direct to foreign sources, clinics that do not demand blood work prior to prescribing, procedures that promote peptides and advertise their use with false health claims, and any clinic that refuses to provide or cannot provide you with documentation of their regulatory compliance.
Particularly, the TGA has cautioned against the promotion of peptides on social media by influencers and unqualified individuals with claims that are often false, misleading, exaggerated or advertising products that are illegal, unapproved or unsafe. The same thing can be said about clinic marketing materials.
It is a question that is frequently posed and the truth of the matter is that it is dependent on the GP.
Schedule 4 peptides are legally prescribable by any AHPRA-registered doctor who is allowed sufficient clinical justification. No regulatory need of special peptide training. Nevertheless, the vast majority of GPs will openly acknowledge that peptide treatment does not belong to their area of expertise. They might not know the dosing schedule, what blood markers to follow, and how various peptide compounds interact or what regulatory mechanisms have to take place to achieve access to unapproved items.
Certain peptide clinics provide a strong spirit of cooperation between their prescribing physicians and the GP of the patient in his or her area. This mixed approach may be effective: the peptide clinic will deal with the specialist prescribing and monitoring, whereas the GP will deal with a general health, will coordinate the baseline pathology and emergency care in case of need. It also ensures that the normal doctor used by the patient is aware of the medication taken by the patient and this is essential in preventing drug interactions and also in ensuring that a complete medical history is available.
There is no reason why your GP cannot provide that role provided he or she is comfortable administering peptide therapy and has the knowledge to do so without endangering their life. However, when it is not the case, it would be wiser to find a practitioner experienced in a particular manner.
One of the most crucial practical dissimilarities between the two models is cost which deserves to be told.
Assuming your GP orders you a TGA-approved, PBS-listed peptide such as semaglutide with one of the approved indications, the consultation is billed under Medicare and the drug is placed under the PBS. The amount you may pay on the street might be small.
None of that will be the case in case a peptide clinic orders an unapproved peptide under the compounding route. The consultation, the compounding, the dispensing, the shipping and the continuing monitoring are all out of pocket. The overall spending on a peptide therapy programme can simply be in the range of 500 to 1,000 dollars monthly and in most situations there is no Medicare rebate or cover by the private health insurance.
This is not the only financial aspect of this cost difference. It is also indicative of how the regulatory scrutiny of each pathway has been. The Pharmaceutical Benefits Advisory Committee has evaluated PBS-listed drugs in terms of safety, efficacy and cost-effectiveness. This level of evaluation has not been done on compounded peptides.
The greatest distinction between what a general medical clinic prescribes and what a peptide clinic prescribes is, perhaps, the quality of evidence behind each treatment.
The peptide drugs used in the general practise such as insulin, GLP-1 agonists and somatostatin analogues have undergone Phase I trials, Phase II trials and Phase III trials. They have put in place dosing guidelines, familiar side-effect profiles and decades or years of post-marketing surveillance information. This is the preferred standard of evidence that TGA approval needs.
Most of the peptides being prescribed by the specialist peptide clinics have not gone through this process. An example of which is the BPC-157, which has substantial preclinical information, but nearly no substantial human clinical trial information. There exist some clinical pharmacokinetic and limited efficacy data of CJC-1295 and ipamorelin. The evidence base is frequently encouraging but scanty and that is exactly why these compounds are yet to pass through TGA approval.
This does not imply that the peptide clinics are functioning recklessly. They have most practitioners who are truly knowledgeable and remain up to date as to the research and exercise a cautious, monitored strategy. However, it does not mean that patients should not have the knowledge of what they are agreeing to. When selecting peptide therapy in a specialist clinic, it is likely that you will take a greater risk of not knowing the consequences and long-term safety and risk compared to when taking a fully approved drug with your GP.
General medical and peptide clinic Australia serve under similar regulations even though they have different functions. Approved peptide drugs with high evidence, Medicare reimbursable and well-known safety profiles will be appropriate with your GP. A specialist peptide clinic is available where a wider selection of compounds with more specialised monitoring is available at a much higher price, and with a less comprehensive evidence base.
Each of the models is neither better nor worse. The correct decision is what you need, what facts you are comfortable working with and how much you would want to put in it. It is more important to note that regardless of the path one takes, the practitioner must be registered by AHPRA, the pharmacy must be licenced by TGA, the monitoring must be sufficient and the risks must be disclosed in a honest manner.
The Australian peptide therapy market is changing rapidly. The regulation is becoming stricter, evidence is mounting and the borderline between general practise and specialist peptide medicine might change with time. At this moment, the most important step you can make towards making a sound decision concerning your own health is to understand the differences between these two models.